Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database
**Background:** Pulmonary arterial hypertension (PAH) is a disease characterized by dyspnea, fatigue, chest pain and syncope. As there is no known cure for PAH, the goal of treatment is to control symptoms and slow disease progression. Sildenafil, a phosphodiesterase-5 inhibitor, has been indicated...
Saved in:
Main Authors: | Ariel Berger, John Edelsberg, Simon Teal, Marko A. Mychaskiw, Gerry Oster |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2014-02-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://jheor.org/article/9871-use-of-sildenafil-in-pulmonary-arterial-hypertension-findings-from-a-u-s-healthcare-claims-database |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sildenafil Treatment of Primary Pulmonary Hypertension
by: Kevin B Laupland, et al.
Published: (2003-01-01) -
Development of a Novel Algorithm to Identify People with High Likelihood of Adult Growth Hormone Deficiency in a US Healthcare Claims Database
by: Kevin C. J. Yuen, et al.
Published: (2022-01-01) -
Rosuvastatin, Sildenafil and Their Combination in Monocrotaline-Induced Pulmonary Hypertension in Rat
by: Jasińska-Stroschein Magdalena, et al.
Published: (2014-09-01) -
Comparison of Milrinone with Sildenafil for the Treatment of Persistent Pulmonary Hypertension of the Newborn
by: Imtiaz Ahmad, et al.
Published: (2024-06-01) -
Addition of Sildenafil in Patients with Pulmonary Arterial Hypertension with Inadequate Response to Bosentan Monotherapy
by: Nancy R Porhownik, et al.
Published: (2008-01-01)